Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. with an expected ticker transition to AGPU, generates news at the intersection of AI‑driven oncology, capital markets activity, and digital asset‑enabled AI infrastructure. Company announcements emphasize its use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients, as well as its newer digital asset treasury strategy focused on ATH, the native utility token of the Aethir network.
News updates frequently cover financial results and corporate updates, including quarterly earnings releases, shareholder letters, and discussions of operating performance. These communications often describe progress in validating proprietary technologies, such as the PEDAL AI platform and the ChemoFx live‑cell tumor profiling assay, along with efforts to expand the availability of ChemoFx in the United States and prepare for a de novo launch in Europe.
Investors following POAI can also expect transaction and financing news, such as private placements involving cash and digital assets, reverse stock split announcements, at‑the‑market offering updates, and standby equity purchase agreements. Recent disclosures describe substantial private investment in support of the company’s digital asset treasury strategy, as well as Nasdaq compliance updates related to stockholders’ equity and bid price requirements.
Another recurring theme in the news flow is strategic partnerships and governance developments. Examples include the strategic collaboration with Every Cure on drug repurposing, collaborations related to 3D liver toxicity models, and appointments of new board members and senior leaders to support the digital asset treasury and AI initiatives. Updates on the evolution of the company’s business model, including the creation of a Strategic Compute Reserve through ATH holdings on the Aethir ecosystem, are also highlighted.
For readers and investors, the POAI news page provides a consolidated view of these developments, allowing closer tracking of the company’s oncology‑focused AI activities, its digital asset strategy, and key regulatory and listing milestones.
Predictive Oncology (NASDAQ: POAI) announced an expansion of its services through GMP facility qualifications at its subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. Soluble Biotech's facility in Alabama will enhance its ability to develop formulations for clinical trials, broadening its customer base and fostering long-term partnerships. TumorGenesis in Massachusetts will produce cancer cell media to facilitate research on ovarian and breast cancer cells. These developments aim to improve collaboration with pharmaceutical companies and enhance research capabilities.
Predictive Oncology (NASDAQ: POAI) has successfully completed a registered direct offering of 15,520,911 shares of common stock and warrants, generating approximately $21.34 million in gross proceeds. The offering was priced at $1.375 per share, with warrants exercisable at $1.25 each upon increasing authorized stock to 200 million shares. The funds will be allocated for working capital purposes. H.C. Wainwright & Co. served as the exclusive placement agent for this offering, which was executed under an effective shelf registration statement.
Predictive Oncology (NASDAQ: POAI) has announced a registered direct offering, securing agreements with institutional investors for the sale of 15,520,911 shares at $1.375 each, accompanied by warrants for the same number of shares at an exercise price of $1.25. The offering, totaling approximately $21.34 million in gross proceeds, is set to close around June 15, 2021. Proceeds will primarily fund working capital. The warrants will be exercisable upon increasing authorized shares to 200 million and expire three years thereafter.
Predictive Oncology (NASDAQ: POAI) announced its subsidiaries Helomics, TumorGenesis, and Soluble Biotech will participate in the BIO DIGITAL conference from June 10-11 & 14-18, 2021. The event, featuring over 2,600 participating companies, focuses on biotechnology partnerships and innovations. Helomics aims to leverage its PeDAL™ platform for precision medicine, while Soluble Biotech showcases its rapid formulation development technology. TumorGenesis emphasizes its unique media for culturing cancer cells accurately, enhancing research capabilities.
Predictive Oncology (NASDAQ: POAI) announced a partnership with Cellevate AB to combine resources for advancing cancer research. This collaboration, focusing initially on ovarian cancer, aims to utilize TumorGenesis' specialized media and Cellevate's engineered matrix materials. Their goal is to enhance the development of cancer treatments, addressing the high failure rates in drug approval processes that exceed $2 billion. The partnership signifies an important step toward providing researchers with advanced tools for combating difficult diseases.
Predictive Oncology (Nasdaq: POAI) reported a net loss of $0.11 per share for Q1 2021, compared to a loss of $0.93 in Q1 2020. The company recorded revenue of $280,317, down from $294,943 in the prior year. Cash and cash equivalents reached $27.3 million, up from $3.1 million a year earlier, after net proceeds of $35.6 million from equity transactions. Total stockholders' equity increased to $35.5 million. Significant developments include a contract with a major pharmaceutical company for protein formulation and the initiation of a drug repurposing project focused on ovarian cancer.
Predictive Oncology (NASDAQ: POAI) has appointed Dr. Christina Jenkins to its Board of Directors. Dr. Jenkins, a strategic advisor and venture investor, has extensive experience in clinical medicine and healthcare investment. Her previous role as CEO of OneCity Health Services involved managing a $1.2B initiative aimed at improving care models for 1 million lives. The company anticipates that Dr. Jenkins will provide valuable insights and enhance its strategic position in the market.
Predictive Oncology (NASDAQ: POAI) has appointed J. Melville Engle as the new Chief Executive Officer, retaining his position as Chairman of the Board. Engle, who joined the board in 2016, brings over 20 years of leadership experience in biotechnology and healthcare. He replaces Dr. Carl I. Schwartz, who has retired. Engle's past achievements include significant sales growth at Dey L.P., transforming its product strategy, and driving organizational success in several reputable companies. The company aims for growth through Engle's extensive expertise in biopharmaceuticals.
Predictive Oncology (NASDAQ: POAI) reported its financial results for 2020, recording revenue of $1,252,272, a decline from $1,411,565 in 2019. The company strengthened its balance sheet with net proceeds of $12,952,689 through debt and equity offerings. Significant acquisitions include Soluble Therapeutics and Quantitative Medicine, aimed at enhancing drug discovery capabilities. The gross profit margin increased to 64%, while operational expenses decreased to $2,351,709, showcasing cost management efforts. However, the company faced net losses of $25,884,397, growing from $19,390,766 in 2019.
Predictive Oncology (NASDAQ: POAI) announced the development of a new Generation 3 STREAMWAY® System aimed at enhancing fluid waste management within medical facilities. This updated system features a 25% size reduction, portable installation options, and an automated dripless design for improved reliability. The company will not require a separate FDA submission for the device, ensuring streamlined approval. CEO Dr. Carl Schwartz indicated that a Generation 3 Plus model will follow, integrating an on-board vacuum pump.